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Abstract
Background: Dual antiplatelet therapy consists of administering antiplatelet (antiaggregant) drugs (clopidogrel 
and aspirin) to prevent thrombotic processes, as a preventative measure in patients with acute coronary disease, or 
in patients subjected to percutaneous coronary intervention. 
Objective: The purpose of this study was to evaluate the efficacy of a protocol for performing dental extraction in 
patients receiving dual antiplatelet therapy. 
Material and Methods: �hirty-two patients undergoing dental extractions were included in the study. �he vari-
ables evaluated were: collagen-epinephrine fraction, collagen- adenosine diphosphate fraction, surgical surface, 
post-surgical measures, and adverse effects. Alveolar sutures and gauzes impregnated with an antifibrinolytic 
agent (tranexamic acid), which the patient pressed in place for 30 minutes, were applied to all patients as post-
surgical measures. Descriptive statistics were calculated and analyzed with Student’s t-test to compare pairs of 
quantitative variables; simple regression analysis was performed using Pearson’s correlation coefficient. Statisti-
cal significance was set at p<0.05. 
�esults: Collagen/epinephrine fraction was 264.53±55.624 seconds with a range of 135 to 300 seconds, and col-
lagen/�DP fraction was 119.41±44.216 seconds, both values being higher than normal. �s a result of the post-
surgical measures taken, no patients presented post-operative bleeding, hematoma or infection. 
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Conclusions: Dental extraction was safe for patients receiving dual anti-platelet therapy when using sutures and 
gauze impregnated with tranexamic acid, which the patient pressed in place for 30 minutes. 
Key words: Aspirin, clopidogrel, tranexamic acid, dental extraction, platelet function.
Introduction 
Hemostasis is the set of mechanisms that impede the 
loss of blood through fibrin formation (clotting). This 
process consists of three phases: i) vascular phase, in 
which transitory neurogenic vasoconstriction is pro-
duced, reducing the escape of blood (for a duration of 
about 20 seconds); ii) platelet phase, in which platelet 
thrombus formation takes place at the same time as 
platelet aggregation, which concentrates a large number 
of factors necessary for the third phase; iii)  plasma 
coagulation consists of the complex sequence of pro-
teolytic reactions that bring about fibrin clotting, with 
clots beginning to develop within 15-20 seconds. �his 
process is initiated by activating substances secreted by 
blood vessel, platelets and blood proteins adhering to 
blood vessel walls, known as coagulation factors (1).
Dual antiplatelet therapy consists of the combination of 
two antiaggregant drugs (usually clopidogrel and aspi-
rin) and has two indications: the prevention of throm-
botic processes (cerebrovascular accidents, CV�), and 
the prevention of acute myocardial infarction (�MI) 
in patients with acute coronary syndromes or patients 
subjected to percutaneous coronary intervention (stent) 
(2,3).
Platelets play a central role in the pathogeny of throm-
botic processes; platelet inhibiting drugs are used to 
prevent these processes. Widespread research has 
shown that aspirin produces undisputed benefits in the 
secondary prevention of vascular complications. �spi-
rin’s antiplatelet action is due mainly to the irreversible 
inhibition of cyclooxigenase activity by acetylation of 
this enzyme’s serine hydroxyl group (4).
�he search for other drugs with few adverse effects has 
led to research into clopidogrel, an antiplatelet agent 
derived from thienopyridine that antagonizes platelet 
aggregation induced by adenosine diphosphate (�DP). 
Clopidogrel was evaluated in a 1996 C�P�IE (clopi-
dogrel versus aspirin in patients at risk of ischaemic 
events) trial (5) that compared a 325 mg daily dose of 
aspirin with 75 mg of clopidogrel daily. Clopidogrel 
was found to be superior to aspirin in the prevention 
of the combined risk of CV�, �MI, and cardiovascu-
lar mortality. But when individual complications were 
analyzed separately, it was found that this superiority 
was only maintained in the patient group with sympto-
matic peripheral arterial disease (P�D).  �s aspirin and 
clopidogrel have different mechanisms of action, it was 
thought that the combination of the two would boost the 
prevention of cardiovascular complications (6). When 
patients receiving antiplatelet therapies require dental 
extractions, it is essential to ensure adequate hemor-
rhage and hematoma management. Oral surgery proce-
dures can be modified to minimize the risk of intra- and 
post-operative bleeding. 
In this context, the objective of this study was to evalu-
ate the efficacy of a protocol for performing dental ex-
traction in patients receiving dual antiplatelet therapy.
Material and Methods  
-Patients 
�he study included 32 patients attending the Dental 
Medicine Service of Jaén Hospital’s Neurotrauma Cent-
er (Jaén, Spain) who were to undergo dental extractions. 
�he subjects were all patients who had suffered myo-
cardial infarction or heart disease necessitating coro-
nary revascularization and stent placement within the 
preceding year. �ll patients had been prescribed two 
platelet antiaggregants (clopidogrel and aspirin) as pre-
vention against thromboembolic accidents. �ll subjects 
gave their informed consent to take part and their full 
medical histories were recorded. Patients prescribed any 
medication that would alter hemostasis were excluded 
from the trial, as were those with terminal diseases, or 
with major risks of mortality, or who needed extractions 
involving osteotomies. �he protocol of the study was in 
accordance with the Declaration of Helsinki and was 
approved by the Ethics Committee of University of Gra-
nada (nº FOD/G�/29/2011).
-Variables
Variables analyzed in the trial were: collagen-epine-
phrine fraction, collagen-�DP fraction, surgical sur-
face, post-surgical measures, and adverse effects.  
Collagen-epinephrine fraction and collagen-�DP frac-
tion are two figures derived from a test that evaluates 
platelet function using a platelet function analyzer 
(PF�-100®, Siemens, Munich, Baveria, Germany) that 
aspirates blood through two discs containing different 
agonists to platelets  (collagen-adrenalin and collagen-
�DP). It measures the time taken to close the discs in-
ternal orifice (obturation time). Normal values range 
between 71 and 119 seconds for the disc with collagen/
�DP. �he platelet function test times are prolonged in 
cases of thrombocytopenia or thrombopathia, and so 
the delay in obturation with collagen/adrenalin is char-
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acteristic of patients who consume aspirin or other non-
steroidal anti-inflammatory drugs (NSAIDs), while the 
prolongation of obturation time with collagen-�DP 
occurs in patients consuming antiaggregant inhibitors 
of �DP (clopidogrel, dipiridamole) (for example, in pa-
tients with von Willebrand disease).
�o perform surgical surface evaluation, points were 
scored for each type of tooth or the alveolar surface 
it occupied (1 point for upper and lower incisors, 1.5 
points for canines and premolars, 2 points for molars) in 
order to assess a possible relation between the incidence 
of complications and alveolar surface occupied by the 
tooth. �he same post-surgical measures were applied 
to all patients. Surgery was not begun until a favora-
ble report (coagulation test results) had been submitted 
by the hematologist. �he local anesthetic used was ar-
ticaine with 0.5 mg of epinephrine (Ultracain® 0.5%. 
Normon S.L., Barcelona, Spain), except in patients with 
intolerance to local anesthetics or excessive response 
to epinephrine (in which case mepivacaine without 
epinephrine was used). �ll alveolae were sutured with 
2-0 silk and a curved triangular needle (Normon S.L., 
Barcelona, Spain), which aimed to close the gingival 
margins and so improve hemostasis. When sutured, the 
patient was given gauze impregnated with tranexamic 
acid (Amchafibrin®, Rottapharm Madaus S.L., Barce-
lona, Spain), which he/she was asked to bite on for 30 
minutes. �fterwards the patient was examined again to 
ensure that the hemorrhage had been stopped. When 
this had been established, the patient was given a packet 
of sterile gauzes and an ampoule of tranexamic acid and 
sent home. �he secondary effects evaluated were: none 
(0 points); bleeding [1]; hematoma [2]; infection [3]; oth-
ers [4]. 
-Statistical analysis 
Descriptive statistics were calculated (arithmetic mean, 
standard deviation, ranges and percentages). Student’s 
t-test was applied to compare quantitative variables 
(pairs of mean values). Simple regression analysis was 
also applied using the Pearson correlation coefficient. 
Statistical significance was set at p<0.05.
Results
Of the 32 patients, 13 were men (40.6%) and 19 women 
(59.4%), with ages ranging from 43 to 84 years (mean 
age 71.03±9.14 years). �he mean value for collagen/
epinephrine fraction was 264.53±55.624 seconds with 
a range of 135-300 seconds, without significant differ-
ences in relation to sex (p=0.56). �he mean value for 
collagen/�DP fraction was 119.41±44.216 seconds with 
a range of 95-300 seconds without significant differ-
ences in relation to sex (p=0.33). Both fraction values 
were higher than the normal laboratory figures. No pa-
tient presented bleeding after surgery.  �he mean value 
obtained for surgical surface was 2.016±0.6896 points 
ranging between 1 and 4 points, without significant dif-
ferences in relation to sex (p=0.68).
�he following parameters were found to be unaffected 
by patient age: collagen/epinephrine fraction (r=0.194; 
p=0.28), collagen/�DP fraction (r=-0.046; p=0.80), 
surgical surface (r=-0.005; p=0.97) (�able 1). Collagen/
epinephrine fraction did not influence either collagen/
�DP fraction (r=0.292; p=010), or surgical surface (r=-
0.028; p=0.88) (�able 2). �s a result of the post-surgical 
measures taken, no patient presented either hematoma 
or infection after dental extraction.
Variable r
Col/Epi Fraction 0.194 
Col/�DP Fraction -0.046 
Surgical surface  -0.005 
Table 1. Correlation between age and 
other variables.
r: Correlation coefficient. Col/Epi Frac-
tion: collagen/epinephrine fraction; 
Col/�DP Fraction: collagen/�DP frac-
tion.
Variable r Probability Influence
Col/�DP Fraction 0.292 p>0.05 No influence
Col/�DP Fraction -0.028 p>0.05 No influence
Table 2. Correlation between Col/Epi fraction and other vari-
ables.  
r: Correlation coefficient; Col/ADP Fraction: collagen/ADP 
fraction.
Discussion
�reatment involving oral surgery in patients with plate-
let function disorders must attend to the nature and se-
verity of the disorder as well as type, localization and 
extent of the proposed surgical intervention. �he level 
of risk will depend on sufficient access to the surgical 
site to allow adequate local hemostasis management. 
Without adequate management, hemorrhage and he-
matoma can cause obstruction of the airway, placing the 
patient’s life in danger.
�mong the various measures available for minimizing 
the risk of intra- and post-operative bleeding, the most 
important are: to minimize trauma; avoid flaps; to use 
surgical techniques that facilitate suturing; cauteriza-
tion; all the measures necessary for good hemostasis 
management; and the removal of all granulation tissue 
from areas of chronic inflammation (7).
� hematological study (coagulation test) is made prior 
to oral surgery and this should take place within 24 
hours before surgery, although in the case of extrac-
tions in series, the test results should remain valid for 
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up to two weeks, taking into consideration the patient’s 
behavior following each surgical session. Once the two-
week period is up, a new coagulation test must be made 
if further extractions are to be performed. 
In the present study of platelet function, collagen/epine-
phrine and collagen/�DP fractions increased due to the 
fact that in all cases patients had been prescribed medi-
cation that altered platelet function (clopidogrel and 
aspirin). In 2006, �rrieta-Blanco et al. (8) published a 
study that evaluated the efficacy of the PFA-100 platelet 
function analyzer. Samples were taken from 33 patients 
aged between 24 and 80 years, all receiving antiplatelet 
treatment, who underwent oral surgery. �hey were sub-
jected to a bleeding time test using the Ivy method, an 
international normalized ratio (IN�) test carried out on 
the same day, and a Coagucheck an hour before surgery, 
as well as evaluation of bleeding time by the PF�-100. 
�he authors found the PF�-100 platelet function ana-
lyzer for the measurement of bleeding time to be more 
precise in comparison with the traditional Ivy method.
Platelet antiaggregant drugs are associated with in-
creased bleeding time and higher risk of post-operative 
hemorrhage (9,10). For this reason, some dentists still 
recommend the interruption of therapy by these drugs 
(mainly aspirin) at least three days before any oral sur-
gery procedure. But interrupting the use of the drugs 
exposes the patient to a risk of vascular problems with a 
potential for severe morbidity (11).
The use of antifibrinolytic agents (tranexamic acid and 
epsilon aminocaproic acid), is an approach described 
by many researchers as an element of oral surgery pro-
tocols, but there is great disparity in the ways, means 
and times of their use (12-14). Some authors have rec-
ommended the combination of local antifibrinolytic 
therapy (tranexamic acid) and hemostatic agents as an 
effective prevention against post-operative hemorrhage 
(15). Others suggest that many patients can undergo sur-
gical treatments safely without interrupting their usual 
therapeutic anti-coagulation regime and without any ad-
ditional medical intervention (16) by using tranexamic 
acid locally as a post-operative antifibrinolytic agent for 
two days (17). Meanwhile, others (18) have used human 
fibrin as a hemostatic agent.  
�akocz et al. (19) used a fibrin gel to prevent hemor-
rhage in patients with hemorrhagic disorders, but the 
high economic cost restricts this approach. Other re-
search has rejected the use of fibrin gel due to the risk of 
viral infections (20). Platelets are a natural deposit for 
growth factors such as platelet-derived growth factor, 
transformation growth factor beta, insulin-like growth 
factor, and epithelial growth factor (21).  For this rea-
son, many doctors use autologous platelet concentrate 
to allow the healing process in patients receiving anti-
coagulation therapy before they undergo cardiovascular 
surgery, as this runs a high risk of hemorrhage (14). 
�he present work used a tamponade of gauze soaked in 
tranexamic acid for 30 minutes; patients were advised 
to swallow saliva, not to spit, and not to talk during this 
period. �he technique stopped bleeding successfully by 
retaining blood clots and allowing them to coagulate as 
well as possible. �ojas et al. simplified the process apply-
ing the tamponade of tranexamic acid soaked gauze for 
ten minutes after extraction (22). Sindet-Pedersen et al. 
also recommend applying gauze soaked in tranexamic 
acid immediately following dental extraction, applying 
pressure for several minutes, followed by mouthwashes 
(4.8% aqueous solution of tranexamic acid) every six 
hours for seven days (23).
�nother controversial issue is the use of surgical su-
tures, which varies from protocol to protocol. For some 
researchers, suturing is to be avoided (24,25), and if nec-
essary, non-resorbable sutures should be used, as these 
prevent inflammatory responses that would have a fibri-
nolytic action on blood clotting (26). For others, such as 
Brewer, both resorbable and non-resorbable sutures can 
be used, depending on the dentist’s individual criteria 
and skill; the only problems with non-resorbable su-
tures is that they require a post-operative visit (4-7 days 
later) and there is a possibility of hemorrhage when the 
sutures are removed (27). In the present study, sutur-
ing was taken as a norm following all extractions. �he 
suture material used was 2-0 silk with a curved trian-
gular needle for better closure of the gingival margins, 
which was seen to improve hemostasis considerably. 
�he stitches were removed 8-10 days after extraction. 
�he duration of the therapy is another controversial top-
ic, varying in the literature from six months up to two 
years, twelve months being the most commonly used 
duration (28).
Lastly, comparing the present results with Napeñas et 
al. (29) and Lillis et al. (30), which compared compli-
cations arising in patients with simple antiagreggation 
versus patients receiving dual therapy, the incidence of 
complications in the present study was very low.
   
Conclusion
Dental extraction in patients receiving dual antiagreg-
gant therapy was made safe by using a protocol that kept 
trauma to a minimum, used non-resorbable sutures, and 
applied an antifibrinolytic agent (gauze impregnated 
with tranexamic acid) that the patient held in place un-
der pressure for 30 minutes.   
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